晚期结肠癌行西妥昔单抗联合FOLFIRI化疗的临床分析
|
摘要
目的研究在晚期结肠癌患者的治疗过程中运用西妥昔单抗联合FOLFIRI化疗的治疗方式对患者所起到的影响作用。方法方便选取该院在2015年9月—2018年9月收治的88例晚期结肠癌患者,将其随机分为A组与B组,各为44例,A组患者采用单纯的FOLFIRI化疗,B组患者综合采用西妥昔单抗联合FOLFIRI化疗,从治疗总有效率、毒副反应发生率、生存质量的差异等方面对于不同治疗效果进行数据的收集整理与对比分析。结果对全部的试验对象采用不同的治疗方式之后,A组患者治疗效果中完全缓解2例,部分缓解20例,稳定14例,进展8例,治疗总有效率50.00%;B组患者治疗效果中完全缓解5例,部分缓解24例,稳定13例,进展2例,治疗总有效率65.91%。在治疗总有效率方面B组患者比A组患者要高,A组B组差异有统计学意义(χ~2=4.950,P<0.05)。在治疗之前两组患者的生存质量差异无统计学意义(P>0.05),经过治疗之后,B组患者的生存质量得到了显著的改善与提升,差异有统计学意义(P<0.05)。在不良作用的发生上,A组患者血小板减少12例,白细胞减少14例,肝功能受损15例,恶心呕吐32例;B组患者血小板减少11例,白细胞减少14例,肝功能受损13例,恶心呕吐33例。在不良反应发生率方面两组患者,差异无统计学意义(P>0.05)。结论把西妥昔单抗联合FOLFIRI化疗运用于晚期结肠癌的治疗过程中能够有效促进患者临床症状的改善,具有重要的临床推广应用价值。
Objective To study the effect of treatment with cetuximab combined with FOLFIRI chemotherapy on patients with advanced colon cancer. Methods 88 patients with advanced colon cancer admitted to our hospital from September2015 to September 2018 were convenient selected and randomly divided into group A and group B, 44 patients each. Group A patients received simple FOLFIRI chemotherapy, group B patients with the combination of cetuximab and FOLFIRI chemotherapy, to collect and compare different treatment effects from the aspects of total effective rate, incidence of toxic side effects and quality of life. Results After all the subjects were treated with different treatment methods, the treatment effect of group A was completely relieved in 2 case, partial remission in 20 cases, stable in 14 cases, and progress in 8 cases. The total effective rate was 50.00%. There were 5 cases of complete remission, 24 cases of partial remission, 13 cases of stabilization, and 2 cases of progress. The total effective rate of treatment was 65.91%. In the total effective rate of treatment, patients in group B were higher than patients in group A, and the difference in group B was statistically significant(χ~2=4.950,P<0.05). There was no significant difference in the quality of life between the two groups before treatment(P >0.05). After treatment, the quality of life of group B was significantly improved, and the difference was statistically significant(P<0.05). In the occurrence of toxic side effects, group A patients had thrombocytopenia in 12 cases,leukopenia in 14 cases, liver function impairment in 15 cases, and nausea and vomiting in 32 cases. Group B patients had thrombocytopenia in 11 cases, leukopenia in 14 cases, and liver function impairment of 13 cases, 33 cases of nausea and vomiting. In the incidence of toxic side effects, the two groups of patients had no significant difference(P >0.05).Conclusion The application of cetuximab combined with FOLFIRI chemotherapy in the treatment of advanced colon cancer can effectively improve the clinical symptoms of patients, and has important clinical application value.
Objective To study the effect of treatment with cetuximab combined with FOLFIRI chemotherapy on patients with advanced colon cancer. Methods 88 patients with advanced colon cancer admitted to our hospital from September2015 to September 2018 were convenient selected and randomly divided into group A and group B, 44 patients each. Group A patients received simple FOLFIRI chemotherapy, group B patients with the combination of cetuximab and FOLFIRI chemotherapy, to collect and compare different treatment effects from the aspects of total effective rate, incidence of toxic side effects and quality of life. Results After all the subjects were treated with different treatment methods, the treatment effect of group A was completely relieved in 2 case, partial remission in 20 cases, stable in 14 cases, and progress in 8 cases. The total effective rate was 50.00%. There were 5 cases of complete remission, 24 cases of partial remission, 13 cases of stabilization, and 2 cases of progress. The total effective rate of treatment was 65.91%. In the total effective rate of treatment, patients in group B were higher than patients in group A, and the difference in group B was statistically significant(χ~2=4.950,P<0.05). There was no significant difference in the quality of life between the two groups before treatment(P >0.05). After treatment, the quality of life of group B was significantly improved, and the difference was statistically significant(P<0.05). In the occurrence of toxic side effects, group A patients had thrombocytopenia in 12 cases,leukopenia in 14 cases, liver function impairment in 15 cases, and nausea and vomiting in 32 cases. Group B patients had thrombocytopenia in 11 cases, leukopenia in 14 cases, and liver function impairment of 13 cases, 33 cases of nausea and vomiting. In the incidence of toxic side effects, the two groups of patients had no significant difference(P >0.05).Conclusion The application of cetuximab combined with FOLFIRI chemotherapy in the treatment of advanced colon cancer can effectively improve the clinical symptoms of patients, and has important clinical application value.
引文
[1]李晓惠.西妥昔单抗与FOLFIRI化疗方案在晚期结肠癌治疗中的临床价值分析[J].中国继续医学教育,2015,7(23):137-138.
[2]王丽华.西妥昔单抗联合FOLFIRI化疗方案治疗晚期结肠癌效果观察[J].河南外科学杂志, 2015(4):69-70.
[3]吕红梅,王翠英. FOLFIRI化疗方案与西妥昔单抗联合治疗晚期结肠癌的疗效分析[J].临床医药文献电子杂志,2017, 4(25):4895.
[4]杜丽坤,王霄鹏,陈克富.西妥昔单抗联合FOLFIRI化疗方案治疗晚期结肠癌疗效观察[J].中外医疗,2016,35(22):117-118.
[5]史昱旻,潘胜美.西妥昔单抗联合不同化疗方案治疗转移性结直肠癌的疗效及安全性观察[J].现代实用医学, 2018(1):72-74.
[6]周翡,张海燕,王静珏,等.伊立替康化疗方案联合高频热疗治疗晚期结直肠癌的临床研究[J].安徽医药,2018, 22(3):470-473.
[7]黄山齐.西妥昔单抗联合FOLFIRI化疗方案治疗晚期结肠癌疗效分析[J].中国卫生标准管理,2017, 8(17):62-64.
[2]王丽华.西妥昔单抗联合FOLFIRI化疗方案治疗晚期结肠癌效果观察[J].河南外科学杂志, 2015(4):69-70.
[3]吕红梅,王翠英. FOLFIRI化疗方案与西妥昔单抗联合治疗晚期结肠癌的疗效分析[J].临床医药文献电子杂志,2017, 4(25):4895.
[4]杜丽坤,王霄鹏,陈克富.西妥昔单抗联合FOLFIRI化疗方案治疗晚期结肠癌疗效观察[J].中外医疗,2016,35(22):117-118.
[5]史昱旻,潘胜美.西妥昔单抗联合不同化疗方案治疗转移性结直肠癌的疗效及安全性观察[J].现代实用医学, 2018(1):72-74.
[6]周翡,张海燕,王静珏,等.伊立替康化疗方案联合高频热疗治疗晚期结直肠癌的临床研究[J].安徽医药,2018, 22(3):470-473.
[7]黄山齐.西妥昔单抗联合FOLFIRI化疗方案治疗晚期结肠癌疗效分析[J].中国卫生标准管理,2017, 8(17):62-64.